AxoGen Inc
NASDAQ:AXGN
Intrinsic Value
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. [ Read More ]
The intrinsic value of one AXGN stock under the Base Case scenario is 12.4 USD. Compared to the current market price of 7.77 USD, AxoGen Inc is Undervalued by 37%.
Valuation Backtest
AxoGen Inc
Run backtest to discover the historical profit from buying and selling AXGN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Company Revenue Jumps 18.7%, Aiming 11-14% Growth
2023-Q4 Earnings Call
The company announced a revenue of $42.9 million for the quarter, marking an 18.7% increase from the previous year. This boost was due to a 10.5% increase in unit volume, a 4.9% improvement in product mix, and a 3.3% rise in pricing. Growth was particularly strong in scheduled procedures, which surged over 25%, while emergent trauma, accounting for about half the revenue, grew by a mid-single-digit percentage. Gross profit climbed to $33.8 million from $30 million, but gross margin fell from 83% to 78.7%, largely due to new facility costs. Operating expenses rose 3.7% to $37 million as sales and marketing expenses grew 11.6% to $22.2 million. However, sales productivity improved, and R&D costs upped by 7.2% to $7.3 million due to regulatory submission costs. The company concluded the quarter with a net loss of $3.9 million, improved from a prior $5.4 million loss, and presented 2024 revenue guidance anticipating a growth rate of 11% to 14%.
Balance Sheet Decomposition
AxoGen Inc
Current Assets | 88m |
Cash & Short-Term Investments | 31m |
Receivables | 25.1m |
Other Current Assets | 31.8m |
Non-Current Assets | 108.8m |
PP&E | 104.3m |
Intangibles | 4.5m |
Current Liabilities | 30.4m |
Accounts Payable | 11.8m |
Accrued Liabilities | 18.7m |
Other Current Liabilities | 6k |
Non-Current Liabilities | 70.7m |
Long-Term Debt | 46.6m |
Other Non-Current Liabilities | 24.1m |
Earnings Waterfall
AxoGen Inc
Revenue
|
159m
USD
|
Cost of Revenue
|
-34.2m
USD
|
Gross Profit
|
124.8m
USD
|
Operating Expenses
|
-146.2m
USD
|
Operating Income
|
-21.5m
USD
|
Other Expenses
|
-254k
USD
|
Net Income
|
-21.7m
USD
|
Free Cash Flow Analysis
AxoGen Inc
What is Free Cash Flow?
AXGN Profitability Score
Profitability Due Diligence
AxoGen Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
AxoGen Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
AXGN Solvency Score
Solvency Due Diligence
AxoGen Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
AxoGen Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AXGN Price Targets Summary
AxoGen Inc
According to Wall Street analysts, the average 1-year price target for AXGN is 13.94 USD with a low forecast of 11.11 USD and a high forecast of 17.85 USD.
Ownership
AXGN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
AXGN Price
AxoGen Inc
Average Annual Return | -14.58% |
Standard Deviation of Annual Returns | 20.29% |
Max Drawdown | -86% |
Market Capitalization | 335.1m USD |
Shares Outstanding | 43 210 000 |
Percentage of Shares Shorted | 3.51% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 428 full-time employees. Its platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Axotouch Two-Point Discriminator. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which ranges from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Its portfolio of products is available in the United States, Canada, Germany, Spain, South Korea, and several other countries.
Contact
IPO
Employees
Officers
The intrinsic value of one AXGN stock under the Base Case scenario is 12.4 USD.
Compared to the current market price of 7.77 USD, AxoGen Inc is Undervalued by 37%.